RATIONALE: Interferon (IFN)-gamma blood tests may improve the current level of diagnostic accuracy for tuberculosis infection. The QuantiFERON-TB Gold (QFT-Gold) has been used in selected populations and shows higher specificity than the tuberculin skin test (TST). OBJECTIVE: To evaluate the QFT-Gold test in unselected patients and assess the level of agreement with the TST. METHODS: The test has been routinely performed on whole blood samples in our microbiology laboratory for 8 months. Demographic, clinical, and microbiological data have been collected and correlated to the QFT-Gold results. MEASUREMENTS AND MAIN RESULTS: Of 318 patients tested, 68 (21.4%) gave an indeterminate (low positive mitogen control) QFT-Gold result. Indeterminate results were significantly overrepresented in patients with a negative TST (28.9% vs. 6.6% in TST-positive patients; p < 0.0001, chi2 test) and were more frequent in patients receiving immunosuppressive therapies than in those who were not receiving such treatments (odds ratio, 3.35; 95% confidence interval, 1.84-6.08; p < 0.0001). After excluding indeterminate results, the concordance between QFT-Gold and TST was significantly lower in Bacille Calmette-Guérin-vaccinated individuals (41.5%) than in nonvaccinated individuals (80.3%) (p < 0.0001). In 11 patients with active tuberculosis (5 culture-confirmed), QFT-Gold provided more positive results than the TST (66.7% vs. 33.3%; p = 0.165). CONCLUSIONS: The QFT-Gold test is feasible in routine hospital use for the diagnosis of tuberculosis infection. As with the TST, immunosuppression may negatively affect the test's performance, with a significant rate of indeterminate results in the most vulnerable population.
RATIONALE: Interferon (IFN)-gamma blood tests may improve the current level of diagnostic accuracy for tuberculosis infection. The QuantiFERON-TB Gold (QFT-Gold) has been used in selected populations and shows higher specificity than the tuberculin skin test (TST). OBJECTIVE: To evaluate the QFT-Gold test in unselected patients and assess the level of agreement with the TST. METHODS: The test has been routinely performed on whole blood samples in our microbiology laboratory for 8 months. Demographic, clinical, and microbiological data have been collected and correlated to the QFT-Gold results. MEASUREMENTS AND MAIN RESULTS: Of 318 patients tested, 68 (21.4%) gave an indeterminate (low positive mitogen control) QFT-Gold result. Indeterminate results were significantly overrepresented in patients with a negative TST (28.9% vs. 6.6% in TST-positive patients; p < 0.0001, chi2 test) and were more frequent in patients receiving immunosuppressive therapies than in those who were not receiving such treatments (odds ratio, 3.35; 95% confidence interval, 1.84-6.08; p < 0.0001). After excluding indeterminate results, the concordance between QFT-Gold and TST was significantly lower in Bacille Calmette-Guérin-vaccinated individuals (41.5%) than in nonvaccinated individuals (80.3%) (p < 0.0001). In 11 patients with active tuberculosis (5 culture-confirmed), QFT-Gold provided more positive results than the TST (66.7% vs. 33.3%; p = 0.165). CONCLUSIONS: The QFT-Gold test is feasible in routine hospital use for the diagnosis of tuberculosis infection. As with the TST, immunosuppression may negatively affect the test's performance, with a significant rate of indeterminate results in the most vulnerable population.
Authors: S A Clark; S L Martin; A Pozniak; A Steel; B Ward; J Dunning; D C Henderson; M Nelson; B Gazzard; P Kelleher Journal: Clin Exp Immunol Date: 2007-08-02 Impact factor: 4.330
Authors: M Bocchino; A Matarese; B Bellofiore; P Giacomelli; G Santoro; N Balato; F Castiglione; R Scarpa; F Perna; G Signoriello; D Galati; A Ponticiello; A Sanduzzi Journal: Eur J Clin Microbiol Infect Dis Date: 2008-05-10 Impact factor: 3.267
Authors: Annie F Luetkemeyer; Edwin D Charlebois; Laura L Flores; David R Bangsberg; Steven G Deeks; Jeffrey N Martin; Diane V Havlir Journal: Am J Respir Crit Care Med Date: 2007-01-11 Impact factor: 21.405
Authors: K Okada; T E Mao; T Mori; T Miura; T Sugiyama; T Yoshiyama; S Mitarai; I Onozaki; N Harada; S Saint; K S Kong; Y M Chhour Journal: Epidemiol Infect Date: 2007-11-08 Impact factor: 2.451
Authors: Jérémie Sellam; Haifa Hamdi; Carine Roy; Gabriel Baron; Marc Lemann; Xavier Puéchal; Maxime Breban; Francis Berenbaum; Marc Humbert; Karin Weldingh; Dominique Salmon; Philippe Ravaud; Dominique Emilie; Xavier Mariette Journal: Ann Rheum Dis Date: 2007-04-24 Impact factor: 19.103
Authors: Eun Young Kim; Ju Eun Lim; Ji Ye Jung; Ji Young Son; Kyung Jong Lee; Yoe Wun Yoon; Byung Hoon Park; Jin Wook Moon; Moo Suk Park; Young Sam Kim; Se Kyu Kim; Joon Chang; Young Ae Kang Journal: BMC Infect Dis Date: 2009-12-15 Impact factor: 3.090